Ocugen Q3 net loss $0.10/share, cash $101.6M; advances OCU400 gene therapy and adds OCU500 mucosal vaccine

Ocugen, Inc.

2022-Q3 EPS reported -$0.28 revenue$1,609,000

Net loss per share $0.10 vs $0.05 YoY; R&D $15.6M (up from $6.3M).
Cash and equivalents $101.6M at Sep 30, 2022; provides runway into Q4 2023.
COVAXIN Phase 2/3 enrollment completed; top-line data expected early 2023.
OCU400 gene therapy: dosing began in Cohort 3 for retinitis pigmentosa; enrollment to complete by year-end; also to enroll LCA CEP290 patients.
Expanded pipeline: OCU500 mucosal COVID-19 vaccine licensed from Washington University; OCU410ST for Stargardt disease.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Ocugen, Inc. reported quarter ended September 30, 2022 results: net income $0.10 net loss per share, EPS $0.10 net loss per share.

Period: quarter ended September 30, 2022
Net income: $0.10 net loss per share
EPS: $0.10 net loss per share
Result: reported results

Exact text from the filing

Ocugen reported a $0.10 net loss per share for the three months ended September 30, 2022, compared to a $0.05 net loss per share for the three months ended September 30, 2021.

View on SEC.gov

Browse all earnings releases →

Ocugen, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-028759

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.